The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | Imetelstat provides durable transfusion independence in lower risk MDS group
In this press briefing, recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Pierre Fenaux of St Louis Hospital, Paris, France, presents data on the use of imetelstat in lower risk myelodysplastic syndrome (MDS) patients. Treatment with imetelstat, a telomerase inhibitor, was shown to provide durable transfusion independence in heavily transfused non-del(5q) lower risk MDS that is relapsed/refractory to erythropoietic stimulating agents.
